Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986156 + Ipilimumab/Nivolumab +/- SBRT in Advanced Solid Malignancies
NCT04021043Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2019
- Primary completion
- Apr 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of BMS-986156 in Advanced malignant solid neoplasm, liver carcinoma, lung carcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2019; status: completed.
02
Drugs
BMS-986156
03
Conditions
Advanced malignant solid neoplasmliver carcinomalung carcinoma
Beyond the preview
Go deeper on NCT04021043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021043.